Immunome INC

Immunome announced its second quarter 2026 financial results, highlighting the FDA's acceptance of the New Drug Application for varegacestat with a PDUFA target action date of April 28, 2027, and providing updates on its clinical pipeline.

Immunome, Inc. reports the successful election of directors and ratification of auditors at its 2026 Annual Meeting.

Immunome announced positive Phase 3 RINGSIDE trial results for varegacestat in desmoid tumors, alongside full-year 2025 financials and an extended cash runway into 2028.

Immunome, Inc. announced the pricing of its underwritten public offering of 18.625 million common shares at $21.50 each, aiming to raise approximately $400 million in gross proceeds.

Immunome, Inc. announced positive topline results from its Phase 3 RINGSIDE trial for varegacestat in desmoid tumors, showing significant improvement in progression-free survival and objective response rates, with an NDA submission planned for Q2 2026.

Immunome, Inc. announced its third quarter 2025 financial results and provided updates on its advancing oncology pipeline, including positive clinical activity for IM-1021.

Immunome, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses and net losses, alongside progress in its oncology therapy pipeline.

Immunome, Inc. reported its first-quarter 2026 financial results, highlighting continued investment in its oncology pipeline and a strong cash position.

Immunome reports increased cash reserves and pipeline progress for Q3 2025, driven by financing activities and R&D investments, despite continued operating losses.

Immunome, Inc. reports increased R&D spending on key oncology programs and a strong cash position, despite continued operating losses and the termination of its AbbVie collaboration.

Immunome, Inc. announces its financial results for the first quarter of 2025, showcasing increased collaboration revenue and advancements in its clinical pipeline.

Immunome, Inc. reported a net loss of $47.1 million for the third quarter of 2024, driven by increased research and development expenses, while highlighting progress in its clinical and preclinical programs.

Immunome, a clinical-stage oncology company, provides an update on its financial results for the year ended December 31, 2024, and outlines key advancements in its targeted therapy development programs.

Immunome's 10-K filing details a separation agreement with a former executive, while also providing insights into the company's strategic direction and pipeline.

Isaac Barchas, a Director of Immunome Inc., sold 83,464 shares of common stock on August 10, 2026.

Kinney Horn, CHIEF BUSINESS OFFICER of Immunome Inc., sold 90,616 shares of common stock on August 4, 2026 for $25.09 per share.

Kinney Horn, CHIEF BUSINESS OFFICER of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Philip Tsai, Chief Technical Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Sandra G. Stoneman, CHIEF LEGAL OFFICER & GC of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Jack Higgins, Chief Scientific Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Immunome, Inc. has filed a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Immunome, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent accounting firm.

Immunome, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, with key proposals including the election of directors and ratification of the company's independent auditor.

Immunome, Inc. has scheduled its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the company's independent accounting firm.

Enavate Sciences and Immunome Aggregator report their beneficial ownership in Immunome, Inc. common stock has been diluted to 4.3% following a recent public equity offering.

Immunome Aggregator, LP, an entity managed by Enavate Sciences GP, LLC, has significantly increased its beneficial ownership in Immunome, Inc. to 6.0% through a recent purchase of shares in the Issuer's 2025 public offering.

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 4.3% of Immunome Inc.'s common stock as of June 30, 2026.

Redmile Group, LLC and Jeremy C. Green have filed a Schedule 13G reporting a 4.9% beneficial ownership stake in Immunome, Inc.

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 14.5% in Immunome Inc. as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 6.1% of Immunome Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Immunome Inc. following an internal corporate realignment.

T. Rowe Price Investment Management, Inc. has disclosed a 12.2% beneficial ownership stake in IMMUNOME INC, holding over 10.6 million shares.